MiR-144/451 deficiency results in erythroid hyperplasia, ineffective erythropoiesis, and anemia. (A) MiR-144/451 deficiency alters several erythrocyte parameters in the peripheral blood. Bar graphs are shown expressing values for RBC, hemoglobin (Hb), hematocrit (HCT); and red cell distribution width (RDW). Bars represent mean values (n = 5), error bars indicate standard deviation. (B) Splenomegaly in miR-144/451−/− mice. Bars represent mean values (n = 5), error bars indicate standard deviation. (C) Erythropoietin (EPO) concentrations in plasma in miR-144/451−/− and wild-type littermate controls. The individual and mean EPO values are plotted for five independent measurements. (D) Representative FACS analysis of erythroid cell populations in the bone marrow and spleen of wild-type and miR-144/451−/− mice. Roman numerals and numbers indicate the identity and percentages of cells of the developmentally defined subpopulations (Socolovsky et al., 2001): I, proerythroblasts; II, basophilic erythroblasts; III, polychromatophilic erythroblasts; IV, orthochromatophilic erythroblasts. (E) Comparative enumeration of erythroid precursors in the bone marrow and spleen of miR-144/451−/− and wild-type mice. Numbers are expressed relative to the wild-type and plotted for the developmentally defined erythroid subpopulations indicated in D by roman numerals. The data in A, B, D, and E are representative of three independent experiments. (F) Survival plot of wild-type (n = 11) and miR-144/451−/− (n = 11) mice treated with phenylhydrazine. As indicated by the arrows, days 0 and 1 mark the days of the first and second injection, respectively. The data represent two independent experiments. *, P < 0.05; **, P < 0.0001.